Urgent treatment solutions are needed for children, adolescents and adults with mental health conditions. Despite the government committing to spending 8.9% of all NHS funding on mental health treatment last year, the pipeline to build new facilities and train new staff will take years and, on their own, are insufficient to meet demand.
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa | Psychedelic Invest
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class